Shares of Gland Pharma Ltd were trading in the green and 2% higher on 20 January after the company announced receiving Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Pashamylaram facility.

The US health regulator conducted an inspection for Good Manufacturing Practices (GMP) at the Pashamylaram facility in Hyderabad between 25 July and 2 August 2024. Following the completion of the inspection, the company received an EIR from the USFDA. 

Earlier on 16 January, the company’s Dundigal Facility in Hyderabad received an EIR from the USFDA indicating the closure of the inspection.

In its regulatory filing, the company said, “Following the inspection for Good Manufacturing Practices (GMP) by the USFDA at the company’s Dundigal Facility in Hyderabad between 22 July, 2024, and 25 July, 2024, the company has received an Establishment Inspection Report (EIR) from the US FDA indicating the closure of the inspection.”

Founded in 1978, Gland Pharma specializes in manufacturing injectable formulations. The company operates eight production facilities across India and markets its products in more than 60 countries. Following a business-to-business (B2B) model, Gland Pharma serves regions such as the United States, Europe, Canada, Australia, India, and other global markets as of 31 March 2022.

The company’s shares have experienced negative trends, declining approximately 17% over the past six months and 13% over the past year.

At 11:24 pm, the shares of Gland Pharma were trading 0.41% higher at Rs 1,686.10 on NSE.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!